Upgrade to SI Premium - Free Trial

Leerink Partners Reiterates Market Perform Rating on Neogenomics (NEO) amid test reimbursements

March 16, 2026 8:28 AM
Leerink Partners analyst Puneet Souda reiterated a Market Perform rating and $14.00 price target on Neogenomics (NASDAQ: NEO)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments